Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001213900-25-118884
Filing Date
2025-12-05
Accepted
2025-12-05 19:06:25
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7249
  Complete submission text file 0001213900-25-118884.txt   8992
Mailing Address 245 FIRST STREET RIVERVIEW II 18TH FLOOR CAMBRIDGE MA 02142
Business Address 245 FIRST STREET RIVERVIEW II 18TH FLOOR CAMBRIDGE MA 02142 239-302-1707
Enveric Biosciences, Inc. (Subject) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-53543 | Film No.: 251554244
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 650 GEORGIA ST #3200 VANCOUVER A1 V6B4P7
Business Address
Braeden Lichti (Filed by) CIK: 0001982476 (see all company filings)

Type: SCHEDULE 13G